Literature DB >> 1697722

Epitope specificity of the protective immune response induced by individual bovine herpesvirus-1 glycoproteins.

S van Drunen Littel-van den Hurk1, G A Gifford, L A Babiuk.   

Abstract

Affinity-purified bovine herpesvirus-1 (BHV-1) glycoproteins gI, gIII and gIV, as well as a virus-free BHV-1-infected cell lysate were injected intramuscularly into seronegative calves. All immunized animals developed specific serum-neutralizing antibodies and they were fully protected from disease, using a BHV-1/Pasteurella haemolytica challenge model. After challenge, viral replication in the nasal passages was significantly reduced in animals vaccinated with gIV (10,000-fold) or BHV-1-infected cell lysate (450,000-fold) but just slightly reduced in animals immunized with gI (500-fold) or gIII (25-fold). All of the known epitopes of the glycoproteins were retained during the affinity-purification or preparation of the cell lysate. The high level of protection induced by gIV and the virus-infected cell lysate in particular indicates the potential of glycoprotein gIV as a subunit vaccine, ideally in combination with component(s) from the cell lysate, which may mediate cellular immune responses.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1697722     DOI: 10.1016/0264-410x(90)90095-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Immunopotentiation of bovine herpes virus subunit vaccination by interleukin-2.

Authors:  H P Hughes; M Campos; D L Godson; S Van Drunen Littel-Van den Hurk; L McDougall; N Rapin; T Zamb; L A Babiuk
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

2.  Bovine herpesvirus 1 VP22 enhances the efficacy of a DNA vaccine in cattle.

Authors:  Chunfu Zheng; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

3.  Ileal and jejunal Peyer's patches play distinct roles in mucosal immunity of sheep.

Authors:  G Mutwiri; T Watts; L Lew; T Beskorwayne; Z Papp; M E Baca-Estrada; P Griebel
Journal:  Immunology       Date:  1999-07       Impact factor: 7.397

4.  Gene gun-mediated DNA immunization primes development of mucosal immunity against bovine herpesvirus 1 in cattle.

Authors:  B I Loehr; P Willson; L A Babiuk
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

5.  Expression of bovine herpesvirus 1 glycoprotein gIV by recombinant baculovirus and analysis of its immunogenic properties.

Authors:  S van Drunen Littel-van den Hurk; M D Parker; D R Fitzpatrick; T J Zamb; J V van den Hurk; M Campos; R Harland; L A Babiuk
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

6.  Constitutively expressing cell lines that secrete a truncated bovine herpes virus-1 glycoprotein (gpI) stimulate T-lymphocyte responsiveness.

Authors:  T P Leary; Y Gao; G A Splitter
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

7.  TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine.

Authors:  Shawn Babiuk; Neeloffer Mookherjee; Reno Pontarollo; Phillip Griebel; Sylvia van Drunen Littel-van den Hurk; Rolf Hecker; Lorne Babiuk
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

8.  Modulation of immune responses to bovine herpesvirus-1 in cattle by immunization with a DNA vaccine encoding glycoprotein D as a fusion protein with bovine CD154.

Authors:  Sharmila Manoj; Philip J Griebel; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

9.  Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA.

Authors:  G J Cox; T J Zamb; L A Babiuk
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

10.  The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides.

Authors:  X P Ioannou; P Griebel; R Hecker; L A Babiuk; S van Drunen Littel-van den Hurk
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.